A double-blind comparison of lisinopril with captopril in patients with symptomatic congestive heart failure
Journal of Cardiovascular Pharmacology
Angiotensin-converting enzyme (ACE) inhibition with captopril is accepted therapy for the treatment of symptomatic congestive heart failure. In this trial, we compared the new ACE inhibitor, lisinopril, to captopril during a 12-week randomized double-blind study. One hundred twenty-nine patients with New York Heart Association class II, III, or IV congestive heart failure were randomized to receive either lisinopril 5 mg/day (n=64) or captopril 37.5 mg/day (n=65) in 15 centers. Drug doses could be titrated upwards every 4 weeks. The primary measure of drug efficacy was improvement in treadmill exercise time using a modified Naughton protocol. Secondary measures of efficacy and the development of adverse effects were also examined. Lisinopril improved exercise time (following 12 weeks of therapy) more than captopril [from 500 ± 30 to 682 ± 34 sec (mean ± SEM) with lisinopril versus 480 ± 26 to 600 ± 35 sec with captopril; difference between groups, p < 0.05]. Adverse drug effects were unusual and similar in frequency in the two groups, although an increase in blood urea nitrogen was more common with lisinopril than with captopril (p<0.05). These results indicate that using the doses and treatment regimens studied, lisinopril is more effective than captopril for the treatment of symptomatic congestive heart failure. Adverse experiences with lisinopril were infrequent and similar in incidence to those observed with captopril.
Powers, E., Chiaramida, A., DeMaria, A., Giles, T., Hackshaw, B., Hart, W., Haugland, M., Johnston, R., Katz, R., & Kirlin, P. (1987). A double-blind comparison of lisinopril with captopril in patients with symptomatic congestive heart failure. Journal of Cardiovascular Pharmacology, 9 (SUPPL. 3). Retrieved from https://hsrc.himmelfarb.gwu.edu/smhs_medicine_facpubs/4230